The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compare treatment with Sepraspray as a adhesion prevention barrier after laparoscopic myomectomy versus no adhesion barrier.

Inclusion Criteria:

• The patient must be a premenopausal women with myomas associated with clinical symptoms deemed suitable for laparoscopic myomectomy and SLL.

Exclusion Criteria:

• Pregnant/lactating women.
• The patient has a history of hypersensitivity to exogenous carboxymethylcellulose products and/or hyaluronic acid.
• The patient's procedure resulted in entry of the endometrial cavity, or entry of the bowel including appendectomy.